Search

Zentalis Pharmaceuticals Inc

Geschlossen

3.82

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.8

Max

3.92

Schlüsselkennzahlen

By Trading Economics

Einkommen

-42M

-78M

EPS

-0.59

Angestellte

106

EBITDA

-42M

-77M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+129.95% upside

Dividenden

By Acuity

Nächstes Ergebnis

6. Nov. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

20M

351M

Vorheriger Eröffnungskurs

3.82

Vorheriger Schlusskurs

3.82

Zentalis Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Aug. 2026, 23:56 UTC

Mettler-Toledo shares are higher in after-market trading, reflecting a broader market rebound amid gains from major stocks like Tesla and UnitedHealth.

21. Aug. 2026, 23:56 UTC

Constellation Energy shares are higher in after-market hours, reflecting broader gains among major stocks. No specific news was identified for the price movement.

21. Aug. 2026, 23:56 UTC

Virtu Financial Inc. shares are higher in after-market trading, following a broader market rebound despite earlier pressures from rising crude oil prices and bond yields.

21. Aug. 2026, 23:56 UTC

TE Connectivity Ltd. shares declined in after-market trading, remaining near the lower end of their one-month range and below the 20-day moving average.

21. Aug. 2026, 23:56 UTC

APA Corp. is trading higher in after-market hours, reflecting broader market strength despite a recent yield-driven selloff. No specific news was identified.

21. Aug. 2026, 23:56 UTC

Social Media

Options trading for Costco includes a notable $950 call option that rose from $0.99 to $2.70. Shares remain roughly flat in after-market trading.

21. Aug. 2026, 23:56 UTC

MercadoLibre Inc. is higher in after-market hours, reflecting routine performance amid broader market gains following earlier pressure from rising crude oil prices and bond yields.

21. Aug. 2026, 23:56 UTC

NiSource shares are higher in after-market trading, reflecting broader market gains following a recent selloff. No specific company news was identified.

21. Aug. 2026, 23:56 UTC

OPKO Health Inc. shares declined in after-market trading, despite gains in major stocks as the broader market rebounded from earlier pressures.

21. Aug. 2026, 23:56 UTC

Agilent Technologies Inc shares are lower in after-market hours, diverging from broader market gains. No specific news was identified to explain the decline.

21. Aug. 2026, 23:56 UTC

Devon Energy Corp shows little change in after-market trading, remaining near unchanged since Friday's close and positioned 8.63% above its 20-day moving average.

21. Aug. 2026, 23:56 UTC

Ginkgo Bioworks Holdings Inc is higher in after-market trading amid a broader market rebound, despite no specific company news identified.

21. Aug. 2026, 23:56 UTC

Equitable Holdings Inc shares are lower in after-market hours, with no specific news identified. The stock remains below its 20-day moving average.

21. Aug. 2026, 23:56 UTC

Correlated Moves

US Bancorp shares are higher in after-hours trading, reflecting positive sentiment in the banking sector amid a broader market rebound.

21. Aug. 2026, 23:56 UTC

Intellia Therapeutics shares are higher in after-market trading, reflecting a broader market rebound following a recent yield-driven selloff.

21. Aug. 2026, 23:56 UTC

Macro News
ETF Constituents

Vanguard Information Technology ETF rises in after-market hours, supported by gains in key holdings like NVIDIA, Apple, and Intuit amid broader market recovery.

21. Aug. 2026, 23:56 UTC

Century Aluminum Co. shares gained after-market, recovering from an earlier dip. The movement reflects broader market trends amid rising crude oil prices and bond yields.

21. Aug. 2026, 23:56 UTC

Correlated Moves

Duke Energy shares rose in after-market trading, reflecting broader market gains despite remaining below the 20-day moving average after four consecutive lower sessions.

21. Aug. 2026, 23:56 UTC

B&G Foods Inc. traded roughly flat during after-market hours with no specific news. The broader market rebounded, but the stock remains near its one-month low.

21. Aug. 2026, 23:52 UTC

South Africa's Balance of Trade Report on August 28, 2026: Analysts Anticipate Continued Surplus Amid Global Economic Instability.

21. Aug. 2026, 23:52 UTC

S&P/Case-Shiller Home Price Index Release on August 25, 2026, Expected to Show Modest Growth Amid Mixed Housing Market Sentiment and Rising Inflation Concerns.

21. Aug. 2026, 23:52 UTC

US GDP Price Index QoQ 2nd Estimate for Q2, forecasted at a 0.063% increase, set to release on August 26 amid rising optimism in economic indicators and inflation concerns.

21. Aug. 2026, 23:52 UTC

XRP is trading higher during Friday's session, supported by a broader cryptocurrency rally and a U.S. Treasury announcement on bond buyback operations.

21. Aug. 2026, 23:51 UTC

Shares of Science Applications International Corp. are lower in after-market trading, reflecting a notable retracement despite being above the 20-day moving average.

21. Aug. 2026, 23:51 UTC

Karyopharm Therapeutics Inc shares are lower in after-market hours, following a brief uptick earlier. No specific news was identified to explain the decline.

21. Aug. 2026, 23:51 UTC

Par Pacific Holdings Inc. shares are lower in after-market hours, continuing a trend within the broader context of its one-month trading range.

21. Aug. 2026, 23:51 UTC

Paylocity Holding Corp shares are lower in after-market trading, with no specific news identified for the decline. The stock remains above its 20-day moving average.

21. Aug. 2026, 23:51 UTC

Shift4 Payments Inc is trading higher in after-market hours, supported by a rally in cryptocurrencies that benefits crypto-exposed equities.

21. Aug. 2026, 23:51 UTC

Coca-Cola Europacific Partners PLC shares are higher in after-market hours, recovering from an earlier dip amid broader market trends and a cryptocurrency rally.

21. Aug. 2026, 23:51 UTC

Kirby Corp shares are higher in after-market trading, reflecting a strong performance that exceeds the 20-day moving average. No specific news was identified.

Peer-Vergleich

Kursveränderung

Zentalis Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

129.95% Vorteil

12-Monats-Prognose

Durchschnitt 8.83 USD  129.95%

Hoch 11 USD

Tief 5 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Zentalis Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

5

Buy

1

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat